Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: the PEMBRO-RT study - Theelen, W; Lalezari, F (J Clinic Oncol, 2018)
(15 Suppl):